

Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors

Pingyu Ding, Paul Helquist and Marvin J. Miller*

Received 27th October 2006, Accepted 13th December 2006


First published as an Advance Article on the web 19th January 2007

DOI: 10.1039/b615603g

Inhibitors of NAALADase have shown promise for a variety of diseases associated with glutamate excitotoxicity, and could be useful for the diagnosis and therapy of prostate cancer. A series of novel enantiomerically pure 2-(phosphonomethyl)pentanedioic acid (2-PMPA) based NAALADase inhibitors were synthesized. These compounds were prepared from previously reported (*S*)-2-(hydroxyphosphinoylmethyl)pentanedioic acid benzyl ester **4**. Biological test results showed that the new compounds are good to outstanding NAALADase inhibitors. Compounds **8b** and **10b** showed activity similar to the known potent inhibitor (*S*)-2-PMPA. Fluorescently labeled inhibitor **19b** may potentially be used to study binding to prostate cancer cells by fluorescence microscopy, and siderophore-containing inhibitor **21b** may be useful for detection of prostate-derived cancer cells by magnetic resonance imaging (MRI).

Introduction


The metalloprotease glutamate carboxypeptidase II (GCP II, also known as *N*-acetylated alpha-linked acidic dipeptidase, NAALADase) releases *N*-acetyl aspartate and glutamate from both the neuronal peptide *N*-acetylaspartylglutamate (NAAG) and folate polyglutamate (Scheme 1).¹ Inhibitors of NAALADase have shown efficacy in a variety of animal models of neurological disease associated with glutamate excitotoxicity.²



NAALADase is also expressed in the human prostate parenchyma, from where it was first cloned and named prostate specific membrane antigen (PSMA).³ It has been shown that inhibitors of NAALADase also strongly bind to PSMA. As a representative member of the phosphinate-based series of binders, VA-033 was found to serve as a potent inhibitor of NAALADase activity associated with PSMA that is expressed on LNCaP human prostate cancer cells and by tumor cells *in vivo*.^{4a} These inhibitors themselves do not affect the viability of the LNCaP cells, nor do they significantly alter cell cycle kinetics. They therefore provide a biologically innocuous scaffold that can be used to target diagnostic markers or chemotherapeutic drugs to the surface membrane of prostate tumor cells. Recent studies have shown that the NAALADase inhibitors may also have more direct therapeutic potential.^{4b}

Over the past decade, tremendous efforts have been made in the development of potent inhibitors of GCP II (Fig. 1).⁵ The first

potent and selective inhibitor was 2-(phosphonomethyl)pentanedioic acid (2-PMPA) reported by Jackson *et al.* in 1996.⁶ Since then, extensive structure–activity relationship studies have been carried out using 2-PMPA as a template, and a few potent inhibitors of GCP II, such as urea-based compounds⁷ and GPI5232⁸ were identified. Berkman's group reported the synthesis of phenylalkylphosphonamides as prostate-specific membrane antigen (PSMA) inhibitors.⁹ Further studies on 2-PMPA have demonstrated that potent inhibition of glutamate carboxypeptidase II (GCP II) is specific to (*S*)-2-PMPA, which has an absolute configuration corresponding to L-glutamate.¹⁰ Recent studies on GPI5232 also showed that the (*S*)-enantiomer is 40-fold more potent than the (*R*)-enantiomer in a GCP II inhibitory assay.¹¹ Therefore, it is essential to synthesize the enantiomerically pure inhibitors prior to further preclinical characterization in order to eliminate the potential for undesired pharmacological effects or other interferences by the inactive enantiomers.




Based on these known results, we became interested in the synthesis of enantiomerically pure phosphonates having the general structure **1** and possessing the (*S*)-configuration. First, the phosphonate group of **1** was intended to both mimic the tetrahedral intermediate formed during hydrolysis of NAAG and inhibit catalytic activity of the enzyme by binding the essential zinc in the active site. Second, the ability to derivatize the inhibitor at position

Walther Cancer Research Center and Department of Chemistry & Biochemistry, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, Indiana 46556, USA. E-mail: mmiller1@nd.edu; Fax: +1 574 631 6652; Tel: +1 574 631 7571

R by linking a suitably labeled head group was anticipated to allow detection of prostate derived cells in circulation by fluorescence or by magnetic resonance imaging (MRI) whilst not impairing the ability of the inhibitor to access the active site.¹² In this paper, we describe the synthesis of a series of novel enantiomerically pure 2-PMPA based derivatives **1** and their inhibitory potencies in a GCP II assay.

Results and discussion

Our first synthesis of a form of **1** focused on preparation of **8a** (Scheme 2). The synthesis of TBS protected alcohol **3** has been previously accomplished by selective deprotection of the corresponding bis(TBS) derivative with I_2 in methanol.¹³ We used the route shown in Scheme 2 to obtain this product in excellent yield. The starting material **2** was readily prepared from ethyl 4-hydroxyphenylacetate.¹⁴ The coupling reaction between **3** and optically pure (*S*)-2-(hydroxyphosphinoylmethyl)pentanedioic acid dibenzyl ester **4**⁵ afforded phosphinate **5** smoothly. Product **5** was then subjected to oxidation by $NaIO_4$ to provide phosphonic acid **6**. Treatment of **6** with $BnBr-K_2CO_3$ in DMF gave benzyl ester **7** in 85% yield, while the esterification reaction employing benzylisourea or using BOP as an activating agent did not give good yields.¹⁵ Desilylation using HF in CH_3CN ¹⁶ gave phenol **8a** cleanly.



Scheme 2

Table 1 Inhibition of GCP II by the proposed inhibitors generated by debenzilation

Compound	R	IC ₅₀ /nM	SEM	n ^a	
8b	CH ₂ CH ₂ (4-OH-C ₆ H ₄)	0.2	0.05	4	
9b	CH ₂ CH ₂ (4-F-C ₆ H ₄)	300	0	2	
10b	CH ₂ CH ₂ (4-BocNH-C ₆ H ₄)	0.1	0.01	4	
11b	CH ₂ CH ₂ C ₆ H ₅	0.8	0.05	2	
12b	CH ₂ CH ₂ CH ₂ C ₆ H ₅	4	2	4	
14b	CH ₂ CH ₂ (4-AcNH-C ₆ H ₄)	4		1	
15b	CH ₂ CH ₂ (4-Boc-Gly-NH-C ₆ H ₄)	0.7	0	2	
16b	CH ₂ CH ₂ (4-Boc-Gly-Pro-NH-C ₆ H ₄)	7		1	
17b	CH ₂ CH ₂ [4-Boc-(Gly) ₃ -NH-C ₆ H ₄]	8		1	
19b		2	0.8	4	
21b		5	2	4	
(<i>S</i>)-2-PMPA		0.4	0.09	4	

^a n = the number of times the assay was performed.

By modification of the above three-step approach for the preparation of benzyl ester **7**, the four benzyl esters **9a–12a** (Fig. 2) were obtained in the indicated overall yields from the corresponding commercially available phenalkanols.






Fig. 2 Benzyl esters **9a–12a**.

Several additional analogs were obtained by elaboration of **10a** (Scheme 3). Thus, Boc deprotection of **10a** gave aniline **13** as a crude oil that was used directly in the next step without purification. Acetylation of **13** provided **14a**. Boc-Gly-OH, Boc-Gly-Pro-OH and Boc-(Gly)₃-OH were also coupled to aniline **13** to give compounds **15a–17a** in excellent yields.



Scheme 3


Removal of the benzyl groups from each of the protected products gave the corresponding potential inhibitors **8b**, **9b**, **10b**, **11b**, **12b**, **14b**, **15b**, **16b**, and **17b** (Table 1). ³¹P NMR analysis of each final acid revealed one sharp singlet, supporting the formation of a single diastereomer.



Scheme 4

As shown in Scheme 4, fluorescent-labeled compound **19b** was prepared in two steps. Refluxing the mixture of free amine **13** and commercially available 7-(diethylamino)coumarin-3-carbonyl-azide **18** in benzene followed by column chromatographic purification in the presence of Et₃N provided the fully protected intermediate **19a** in good yield.¹⁷ To avoid overreduction, debenzylolation was performed by using 1,4-cyclohexadiene in the presence of 10% Pd–C catalyst in MeOH–EtOH (v/v 3 : 1) to give the desired product (**19b**). As will be subsequently reported, this fluorescently labeled compound will be used to study binding to prostate cancer cells by fluorescence microscopy.

Siderophore-containing moiety **21b** was readily obtained in two steps as shown in Scheme 5. The coupling reaction between aniline **13** and tripeptide acid **20**¹⁸ gave the fully protected precursor **21a**. Upon removal of the benzyl protecting groups under standard catalytic hydrogenolysis conditions, conjugate **21b** was obtained in quantitative yield. The iron and gadolinium complexes of this compound will be studied for the detection of prostate cancer cells by MRI.



Scheme 5

The *in vitro* GCP II inhibitory potencies of these obtained PSMA inhibitors were measured at Guilford Pharmaceuticals Inc. using *N*-acetyl-L-aspartyl-[³H]-L-glutamate as a substrate and human recombinant GCP II¹⁹ as previously reported.²⁰ The assay results are shown in Table 1 along with the assay reference compound (*S*)-2-PMPA. Eight concentrations of each inhibitor in the 0.1 pM–1 μM range were evaluated for each IC₅₀ determination. Xcelfit software was used to calculate the IC₅₀ values. We plotted log of concentration vs. % inhibition. The fluoro compound **9b** showed low activity, whereas compounds **8b** and **10b** demonstrated the best activity with IC₅₀ values of 0.2 nM and 0.1 nM, respectively. Compared to compound **11b**, compound **12b** with the increased number of methylene units was five-fold less active. Acetyl derivative **14b** possessed good activity with an IC₅₀ value of 4 nM. Again, compared to compound **15b**, compounds **16b** and **17b**, with the increased side chain length of the amide attached to the phenyl group, had ten-fold decreased activity. Fluorescently labeled inhibitor **19b** and siderophore-containing inhibitor **21b**

displayed activity with IC₅₀ values of 2 nM and 5 nM, respectively, indicating that potentially diagnostically useful labeling groups are compatible with inhibitor design.

Conclusions

Based on the known potent NAALADase inhibitor (*S*)-2-(phosphonomethyl)pentanedioic acid (2-PMPA), we synthesized a series of eleven enantiomerically pure forms of phosphonate **1**. Most of the final products showed good to outstanding NAALADase inhibitory activity. Our studies clearly demonstrate that the bulky, phenyl-derived linker group is tolerated in the newly prepared NAALADase inhibitors. These results should facilitate future development of other NAALADase and PSMA inhibitors. Additional future studies will determine the feasibility of using fluorescently labeled inhibitor **19b** to study prostate cancer cells by fluorescence microscopy. Siderophore-containing inhibitor **21b** will be studied as iron and gadolinium complexes for the detection of prostate cancer cells by MRI. These and other chemical agents are being developed for the early detection and treatment of prostate cancer.

Experimental

All reactions were carried out under argon by using standard techniques. Solvents were dried under nitrogen by standard procedures, distilled before use and stored under argon. NMR spectra were recorded on a Varian Unityplus 300 MHz spectrometer or Varian Inova 500 MHz spectrometer. Optical rotations were recorded on a Perkin Elmer model 343 polarimeter. Mass spectra were recorded on a Jeol JMS-AX505 HA Double Sector mass spectrometer.

2-(4-*tert*-Butyldimethylsilyloxyphenyl)ethanol (**3**)

To a suspension of LiAlH₄ (1.08 g, 28.46 mmol) in THF (70 mL) was added a solution of **2**¹⁴ (4.00 g, 13.58 mmol) in THF (15 mL) portionwise at 0 °C, and the resulting mixture was stirred at that temperature for 1.5 h. Then H₂O (1.1 mL) was added slowly, followed by 1.1 mL of 15% NaOH solution and 1.65 mL of H₂O. After stirring for another 30 min at 0 °C, the mixture was filtered through a Celite pad to remove the resulting white solid. The solid was washed with THF. The combined organic layers were concentrated to provide the crude product which was purified by flash column chromatography on silica gel (hexanes–EtOAc 3 : 1 → 2 : 1) to afford 3.18 g of the product as a colorless oil (93%). ¹H NMR (500 MHz, CDCl₃) δ: 7.08 (d, *J* = 8.5 Hz, 2H), 6.79 (d, *J* = 8.5 Hz, 2H), 3.82 (t, *J* = 6.5 Hz, 2H), 2.81 (t, *J* = 6.5 Hz, 2H), 1.27 (brs, 1H), 0.99 (s, 9H), 0.19 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ: 154.46, 131.11, 130.13, 120.36, 64.03, 38.57, 25.89, 18.39, –4.22.

General procedure for the synthesis of benzyl esters (**7**, **9a**, **10a**, **11a**, and **12a**) from the corresponding phenalkanols

(*S*)-2-[(4-*tert*-Butyldimethylsilyloxyphenyl)ethoxy]-phosphinoyl-methyl-pentanedioic acid dibenzyl ester (**5**). To a solution of **3** (200 mg, 0.792 mmol) and (*S*)-(–)-2-[hydroxyphosphinoylmethyl]-pentanedioic acid dibenzyl ester **4**⁵ (309 mg, 0.792 mmol) in THF (9 mL) were added DCC (172 mg, 0.833 mmol) and DMAP (12 mg, 0.095 mmol). The reaction mixture was stirred overnight,

and the resulting white solid (DCU) was filtered and washed with THF (7 mL). The filtrate was concentrated and purified by flash column chromatography on silica gel (hexanes–EtOAc 3 : 1 → 1 : 1) to afford 346 mg of **5** as a colorless oil (70%). ¹H NMR (500 MHz, CDCl₃) δ: 7.38–7.35 (m, 10H), 7.08 (dd, *J* = 553, 10 Hz, 1H), 7.07–7.04 (m, 2H), 6.80–6.77 (m, 2H), 5.14 (s, 2H), 5.12 (s, 2H), 4.30–4.05 (m, 2H), 3.01–2.80 (m, 3H), 2.43–1.80 (m, 6H), 0.99 (s, 9H), 0.20 (s, 6H); HRFABMS calcd. for C₃₄H₄₆O₇PSi (M + H)⁺ 625.2750, found 625.2731.

(S)-2-[[[4-*tert*-Butyldimethylsilyloxyphenyl]ethoxy]-phosphonoyl]methyl-pentanedioic acid dibenzyl ester (6**).** Compound **5** (327 mg, 0.534 mmol) was dissolved in dioxane–water (5 : 1, 6 mL), and NaIO₄ (134 mg, 0.628 mmol) was added. The reaction mixture was stirred at room temperature for 20 h, and then diluted with EtOAc (150 mL) and water (20 mL). The layers were separated, and the organic layer was washed with saturated aqueous KHSO₄ (25 mL), 0.3 M Na₂S₂O₃ (25 mL), H₂O (20 mL) and brine (25 mL). After being dried, filtered, and concentrated, 335 mg of the product was obtained as a semi-solid (100%). ¹H NMR (500 MHz, CDCl₃) δ: 7.36–7.22 (m, 10H), 7.02 (d, *J* = 8.0 Hz, 1H), 6.67 (d, *J* = 8.0 Hz), 5.09–4.98 (m, 4H), 3.95–3.85 (m, 2H), 2.80–2.70 (m, 3H), 2.32–2.22 (m, 2H), 2.03–1.80 (m, 4H), 1.65–1.55 (m, 1H), 0.93 (s, 9H), 0.11 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ: 176.96 (d, *J* = 6.2 Hz), 174.65, 155.56, 137.72, 137.66, 132.95, 131.18, 129.65, 129.42, 129.31, 129.22, 121.06, 67.74, 67.46, 66.16, 41.90, 37.76, 32.75, 29.71, 29.58, 26.34, 19.15, –4.08; HRFABMS calcd. for C₃₄H₄₅KO₈PSi (M + K)⁺ 679.2253, found 679.2258.

(S)-2-[[[4-*tert*-Butyldimethylsilyloxyphenyl]ethoxy]-phosphonoyl]methyl-pentanedioic acid tribenzyl ester (7**).** Compound **6** (70 mg, 0.109 mmol) was dissolved in DMF (4 mL), and K₂CO₃ (90 mg, 0.655 mmol) and benzyl bromide (78 μL, 0.665 mmol) were added. The resulting mixture was stirred at room temperature for 10 h, diluted with CH₂Cl₂, and washed with cold water and brine. After being dried, filtered, and concentrated, the residual DMF was evaporated under high vacuum. The residue was purified by flash column chromatography eluting with hexanes–ethyl acetate (2 : 1 → 1 : 1 → 1 : 2) to afford 64 mg of product as a colorless oil (85%). ¹H NMR (500 MHz, CDCl₃) δ: 7.42–7.25 (15H, m), 7.06–6.97 (2H, m), 6.80–6.72 (2H, m), 5.18–4.90 (6H, m), 4.17–4.06 (2H, m), 2.84–2.80 (3H, m), 2.35–2.24 (3H, m), 2.07–1.80 (3H, m), 1.00 (9H, s), 0.20 (6H, s); HRFABMS calcd. for C₄₁H₅₂O₈PSi (M + H)⁺ 731.3169, found 731.3138.

(S)-2-[[[4-Hydroxyphenyl]ethoxy]phosphonoyl]methyl-pentanedioic acid tribenzyl ester (8a**).** To a flask containing **7** (280 mg, 0.383 mmol) was added 40% HF–CH₃CN (5 : 95) (21 mL), and the reaction mixture was stirred at room temperature for 6 h and then diluted with EtOAc (100 mL). The layers were separated, and the organic layer was washed with saturated NaHCO₃ solution and brine. After being dried, filtered, and concentrated, the residue was purified by flash column chromatography eluting with hexanes–ethyl acetate (2 : 1 → 1 : 1 → 1 : 2) to afford 200 mg of product as a colorless oil (85%). ¹H NMR (500 MHz, CDCl₃) δ: 7.99–7.93 (1H, m), 7.37–7.32 (15H, m), 6.94–6.91 (2H, m), 6.82–6.80 (2H, m), 5.11–4.94 (6H, m), 4.20–4.01 (2H, m), 2.90–2.78 (3H, m), 2.40–2.23 (3H, m), 2.02–1.77 (3H, m); ³¹P NMR (121 MHz, CDCl₃) δ: 29.30, 29.19; HRFABMS calcd. for C₃₅H₃₈O₈P (M + H)⁺ 617.2304, found 617.2324.

General procedure for the synthesis of final acids (**8b**, **9b**, **10b**, **11b**, **12b**, **14b**, **15b**, **16b**, **17b** and **21b**)

(S)-2-[[[4-Hydroxyphenyl]ethoxy]phosphonoyl]methyl-pentanedioic acid (8b**).** To a solution of **8a** (25 mg, 0.031 mmol) in MeOH (5 mL) was added 10% Pd–C (30 mg). The reaction mixture was stirred under an atmosphere of H₂ for 3 h. The resulting mixture was filtered through a pad of Celite and washed with methanol. The combined solution was evaporated to afford 10.1 mg of the product as a colorless oil (95%). [*a*]_D²⁰ = +4.4° (*c* = 0.75, MeOH); ¹H NMR (500 MHz, CD₃OD) δ: 6.98 (2H, d, *J* = 8.5 Hz), 6.62 (2H, d, *J* = 8.5 Hz), 3.98 (2H, q, *J* = 7.0 Hz), 2.76 (2H, q, *J* = 7.0 Hz), 2.63–2.58 (1H, m), 2.30–2.18 (2H, m), 2.08–2.00 (1H, m), 1.90–1.65 (3H, m); ¹³C NMR (125 MHz, CD₃OD) δ: 177.93, 176.65, 157.26, 131.24, 129.89, 116.37, 67.41, 40.78, 37.33, 32.37, 29.76, 28.62; ³¹P NMR (121 MHz, CDCl₃) δ: 26.05; HRFABMS calcd. for C₁₄H₂₀O₈P (M + H)⁺ 347.0896, found 347.0913.

(S)-2-[[[4-Fluorophenyl]ethoxy]phosphonoyl]methyl-pentanedioic acid tribenzyl ester (9a**).** Yield: 60%. ¹H NMR (500 MHz, CDCl₃) δ: 7.42–7.31 (15H, m), 7.13–7.09 (2H, m), 6.98–6.95 (2H, m), 5.17–4.95 (6H, m), 4.20–4.02 (2H, m), 2.85 (2H, q, *J* = 7.0 Hz), 2.83–2.78 (1H, m), 2.40–2.24 (3H, m), 2.04–1.96 (2H, m), 1.93–1.77 (1H, m); ³¹P NMR (121 MHz, CDCl₃) δ: 29.78; HRFABMS calcd. for C₃₅H₃₇FO₇P (M + H)⁺ 619.2261, found 619.2272.

(S)-2-[[[4-Fluorophenyl]ethoxy]phosphonoyl]methyl-pentanedioic acid (9b**).** Yield: 93%. [*a*]_D²⁰ = +20.4° (*c* = 0.5, MeOH); ¹H NMR (500 MHz, CD₃OD) δ: 7.10–7.04 (2H, m), 6.83–6.77 (2H, m), 3.96 (2H, q, *J* = 6.5 Hz), 2.75 (2H, t, *J* = 6.5 Hz), 2.52–2.43 (1H, m), 2.23–2.05 (2H, m), 2.02–1.93 (1H, m), 1.80–1.58 (3H, m); ³¹P NMR (121 MHz, CDCl₃) δ: 27.23; HRFABMS calcd. for C₁₄H₁₉FO₇P (M + H)⁺ 349.0852, found 349.0834.

(S)-2-[[[4-*N*-*tert*-Butoxycarbonylphenyl]ethoxy]-phosphonoyl]methyl-pentanedioic acid tribenzyl ester (10a**).** Yield: 71%. ¹H NMR (500 MHz, CDCl₃) δ: 7.36–7.24 (17H, m), 7.12–7.02 (2H, m), 6.52 (1H, NH, brs), 5.10–4.92 (6H, m), 4.20–4.01 (2H, m), 2.90–2.73 (3H, m), 2.37–2.19 (3H, m), 2.02–1.72 (3H, m), 1.54 (9H, s); ³¹P NMR (121 MHz, CDCl₃) δ: 29.03, 28.96; HRFABMS calcd. for C₄₀H₄₇NO₉P (M + H)⁺ 716.2988, found 716.2963.

(S)-2-[[[4-*N*-*tert*-Butoxycarbonylphenyl]ethoxy]-phosphonoyl]methyl-pentanedioic acid (10b**).** Yield: 97%. [*a*]_D²⁰ = –32.0° (*c* = 0.5, MeOH); ¹H NMR (500 MHz, CD₃OD) δ: 7.32–7.26 (2H, m), 7.18–7.12 (2H, m), 4.15–3.97 (2H, m), 2.95–2.85 (3H, m), 2.42–1.63 (6H, m), 1.49 (9H, s); ³¹P NMR (121 MHz, CDCl₃) δ: 24.33; MS calcd. for C₁₉H₂₈NO₉P (M + H + Na)⁺ 469.1478, found 469.1490.

(S)-2-[(2-Phenylethoxy)phosphonoyl]methyl-pentanedioic acid tribenzyl ester (11a**).** Yield: 80%. ¹H NMR (500 MHz, CDCl₃) δ: 7.41–7.17 (20H, m), 5.12–4.92 (6H, m), 4.25–4.11 (2H, m), 2.91 (2H, q, *J* = 6.5 Hz), 2.88–2.78 (1H, m), 2.38–2.22 (3H, m), 2.03–1.96 (2H, m), 1.88–1.77 (1H, m); ³¹P NMR (121 MHz, CDCl₃) δ: 29.58, 29.51; HRFABMS calcd. for C₃₅H₃₈O₇P (M + H)⁺ 601.2355, found 601.2349.

(S)-2-[(2-Phenylethoxy)phosphonoyl]methyl-pentanedioic acid (11b**).** Yield: 91%. [*a*]_D²⁰ = +5.8° (*c* = 1.2, MeOH); ¹H NMR (500 MHz, CD₃OD) δ: 7.08–6.95 (5H, m), 3.93 (2H, q, *J* = 7.0 Hz), 2.76 (2H, t, *J* = 7.0 Hz), 2.58–2.40 (1H, m), 2.19–2.01

(2H, m), 1.99–1.51 (4H, m); ^{31}P NMR (121 MHz, CDCl_3) δ : 26.75; HRFABMS calcd. for $\text{C}_{14}\text{H}_{20}\text{O}_7\text{P}$ ($\text{M} + \text{H}$) $^+$ 331.0947, found 331.0959.

(S)-2-[(3-Phenylpropanoxy)phosphonoyl]methyl-pentanedioic acid tribenzyl ester (12a). Yield: 76%. ^1H NMR (500 MHz, CDCl_3) δ : 7.40–7.17 (20H, m), 5.12–5.02 (6H, m), 4.03–3.88 (2H, m), 2.97–2.83 (1H, m), 2.70–2.62 (2H, m), 2.44–2.28 (3H, m), 2.12–1.82 (5H, m); ^{31}P NMR (121 MHz, CDCl_3) δ : 29.59, 29.54; HRFABMS calcd. for $\text{C}_{36}\text{H}_{40}\text{O}_7\text{P}$ ($\text{M} + \text{H}$) $^+$ 615.2512, found 615.2487.

(S)-2-[(3-Phenylpropanoxy)phosphonoyl]methyl-pentanedioic acid (12b). Yield: 93%. $[\alpha]_{\text{D}}^{20} = +5.3^\circ$ ($c = 1.1$, MeOH); ^1H NMR (500 MHz, D_2O) δ : 7.40–7.21 (5H, m), 3.90–3.38 (2H, m), 2.80–2.33 (5H, m), 2.20–1.74 (6H, m); ^{31}P NMR (121 MHz, CDCl_3) δ : 26.04; FABMS calcd. for $\text{C}_{15}\text{H}_{22}\text{O}_7\text{P}$ ($\text{M} + \text{H}$) $^+$ 345, found 345.

(S)-2-[(4-Aminophenyl)ethoxy]phosphonoyl]methyl-pentanedioic acid tribenzyl ester (13). To a solution of **10a** (440 mg, 0.714 mmol) in CH_2Cl_2 (10 mL) was added 1 mL of TFA. The resulting reaction mixture was stirred at room temperature for 1 h and then diluted with CH_2Cl_2 (100 mL). The mixture was washed with saturated aqueous Na_2CO_3 to remove the excess TFA. The separated aqueous layer was extracted with CH_2Cl_2 twice, and the combined extracts were washed with 30 mL of brine, dried over MgSO_4 , filtered and concentrated. The crude product was obtained as a colorless oil, which was not stable and used directly for the next steps without further purification. HRFABMS calcd. for $\text{C}_{35}\text{H}_{39}\text{NO}_7\text{P}$ ($\text{M} + \text{H}$) $^+$ 616.2464, found 616.2469.

(S)-2-[(4-Acetaminophenyl)ethoxy]phosphonoyl]methyl-pentanedioic acid tribenzyl ester (14a). To a solution of crude **13** (80 mg, 0.13 mmol) in CH_2Cl_2 were added Ac_2O (37 μL , 0.39 mmol) and pyridine (32 μL , 0.39 mmol) at 0°C . The reaction mixture was stirred and warmed to room temperature overnight. The volatiles were evaporated and the residue was purified by flash column chromatography eluting with hexanes–ethyl acetate (1 : 2 \rightarrow 1 : 3) to afford 65 mg (76%) of product as a colorless oil. ^1H NMR (500 MHz, CDCl_3) δ : 7.20–7.15 (16H, m), 7.25–7.22 (2H, m), 7.05–7.03 (2H, m), 5.09–4.92 (6H, m), 4.24–4.06 (2H, m), 2.92 (2H, q, $J = 6.5$ Hz), 2.88–2.80 (1H, m), 2.40–2.78 (3H, m), 2.27 (3H, s), 2.05–1.80 (3H, m); ^{31}P NMR (121 MHz, CDCl_3) δ : 29.29; HRFABMS calcd. for $\text{C}_{37}\text{H}_{41}\text{NO}_8\text{P}$ ($\text{M} + \text{H}$) $^+$ 658.2570, found 658.2568.

(S)-2-[(4-Acetaminophenyl)ethoxy]phosphonoyl]methyl-pentanedioic acid (14b). Yield: 83%. $[\alpha]_{\text{D}}^{20} = -12.1^\circ$ ($c = 0.3$, MeOH); ^1H NMR (500 MHz, CD_3OD) δ : 7.41 (2H, d, $J = 8.0$ Hz), 7.14 (2H, d, $J = 8.0$ Hz), 4.12–4.03 (2H, m), 3.66 (2H, t, $J = 7.0$ Hz), 2.73–2.68 (1H, m), 2.30–2.20 (3H, m), 2.04 (3H, s), 1.98–1.85 (3H, m); ^{31}P NMR (121 MHz, CDCl_3) δ : 26.88; FABMS calcd. for $\text{C}_{16}\text{H}_{23}\text{NO}_8\text{P}$ ($\text{M} + \text{H}$) $^+$ 388.1, found 388.1.

General procedure for the synthesis of 15a, 16a and 17a

Compound 15a. To a suspension of aniline **13** (210 mg, 0.341 mmol) and Boc-Gly-OH (72 mg, 0.409 mmol) in CH_3CN (5 mL) were added diisopropylethylamine (71 μL , 0.409 mmol), HOAt (56 mg, 0.409 mmol) and EDCI (79 mg, 0.409 mmol). The reaction mixture was stirred at room temperature for 18 h. After removal of the solvent, the residue was purified by flash

column chromatography eluting with hexanes–ethyl acetate (1 : 4) to provide the product as a colorless oil in 89% yield (234 mg). ^1H NMR (500 MHz, CDCl_3) δ : 8.47 (1H, NH, brs), 7.46–7.24 (17H, m), 7.10–7.05 (2H, m), 5.46 (1H, NH, brs), 5.09–4.94 (6H, m), 4.16–4.02 (2H, m), 3.93 (2H, brs), 2.84–2.72 (3H, m), 2.38–2.20 (3H, m), 1.99–1.71 (3H, m), 1.49 (9H, s); ^{31}P NMR (121 MHz, CDCl_3) δ : 29.17, 29.07; HRFABMS calcd. for $\text{C}_{42}\text{H}_{50}\text{N}_2\text{O}_{10}\text{P}$ ($\text{M} + \text{H}$) $^+$ 773.3203, found 773.3229.

Compound 15b. Yield: 97%. $[\alpha]_{\text{D}}^{20} = -5.4^\circ$ ($c = 1.0$, MeOH); ^1H NMR (500 MHz, CD_3OD) δ : 7.28–7.24 (2H, m), 7.14–6.92 (2H, m), 3.95 (2H, q, $J = 6.5$ Hz), 3.66–3.55 (2H, m), 2.75 (2H, t, $J = 6.5$ Hz), 2.63–2.58 (1H, m), 2.26–1.50 (6H, m); ^{31}P NMR (121 MHz, CDCl_3) δ : 26.04; EI-MS calcd. for $\text{C}_{21}\text{H}_{32}\text{N}_2\text{NaO}_{10}\text{P}$ ($\text{M} + \text{H} + \text{Na}$) $^+$ 526, found 526.

Compound 16a. Yield: 90%. ^1H NMR (500 MHz, CDCl_3) δ : 9.32 (bs, 1H), 7.50–7.01 (m, 19H), 5.51 (bs, 1H), 5.12–4.91 (m, 6H), 4.71 (m, 1H), 4.18–3.90 (m, 4H), 3.59–3.38 (m, 2H), 2.85–2.75 (m, 3H), 2.50–1.79 (m, 10H), 1.45 (s, 9H); ^{31}P NMR (121 MHz, CDCl_3) δ : 29.59, 29.53; ^{31}P NMR (121 MHz, CDCl_3) δ : 26.41; HRFABMS calcd. for $\text{C}_{47}\text{H}_{57}\text{N}_3\text{O}_{11}\text{P}$ ($\text{M} + \text{H}$) $^+$ 870.3731, found 870.3768.

Compound 16b. Yield: 99%. $[\alpha]_{\text{D}}^{20} = -6.7^\circ$ ($c = 0.6$, MeOH); ^1H NMR (500 MHz, CD_3OD) δ : 7.60–7.13 (m, 4H), 4.64–4.52 (m, 1H), 4.20–3.80 (m, 3H), 3.39–3.28 (m, 1H), 2.99–1.64 (m, 15H), 1.45 (s, 9H); ^{31}P NMR (121 MHz, CDCl_3) δ : 26.41; HRFABMS calcd. for $\text{C}_{26}\text{H}_{39}\text{KN}_3\text{O}_{11}\text{P}$ ($\text{M} + \text{H} + \text{K}$) $^+$ 639.1959, found 639.1942.

Compound 17a. Yield: 92%. ^1H NMR (500 MHz, CDCl_3) δ : 9.05 (bs, 1H), 7.95–7.05 (m, 19H), 6.03 (bs, 1H), 5.12–4.90 (m, 6H), 4.20–3.77 (m, 8H), 3.01–2.93 (m, 4H), 2.40–2.21 (m, 3H), 2.05–1.78 (m, 3H), 1.39 (s, 9H); ^{31}P NMR (121 MHz, CDCl_3) δ : 29.40, 29.35; HRFABMS calcd. for $\text{C}_{46}\text{H}_{55}\text{N}_4\text{NaO}_{12}\text{P}$ ($\text{M} + \text{Na}$) $^+$ 909.3452, found 909.3440.

Compound 17b. Yield: 96% yield. $[\alpha]_{\text{D}}^{20} = -7.2^\circ$ ($c = 0.7$, MeOH); ^1H NMR (500 MHz, CD_3OD) δ : 7.56–7.38 (m, 2H), 7.20–7.02 (m, 2H), 4.05–3.93 (m, 3H), 3.80–3.60 (m, 3H), 2.88–1.15 (m, 11H), 1.36 (s, 9H); ^{31}P NMR (121 MHz, CDCl_3) δ : 26.04; HRFABMS calcd. for $\text{C}_{25}\text{H}_{37}\text{N}_4\text{NaO}_{12}\text{P}$ ($\text{M} + \text{Na}$) $^+$ 639.2043, found 639.2011.

Fluorescent-labeled compound precursor (19a). To a solution of aniline **13** (100 mg, 0.162 mmol) in dry benzene (5 mL) were added commercially available (Fluka) 7-(diethylamino)coumarin-3-carbonyl azide **18** (25 mg, 0.087 mmol) and DMAP (16 mg, 0.131 mmol). The resulting mixture was heated to reflux for 12 h. After cooling to room temperature, the solvent was evaporated. The residue was subjected to column chromatographic purification (EtOAc–hexanes–triethylamine 100 : 25 : 1 to 100 : 25 : 0.5) to afford 35 mg of the product as a yellow solid (46%); mp 63 – 65°C ; ^1H NMR (500 MHz, CDCl_3) δ : 8.90 (bs, 1H), 8.60–8.40 (m, 2H), 7.46–7.03 (m, 23H), 6.80–6.45 (m, 1H), 5.14–4.98 (m, 6H), 4.20–4.04 (m, 2H), 3.58–3.41 (m, 3H), 3.01–2.80 (m, 3H), 2.50–2.31 (m, 3H), 2.09–1.74 (m, 4H), 1.42–1.12 (m, 7H); ^{31}P NMR (121 MHz,

CDCl_3) δ : 29.741; HRFABMS calcd. for $\text{C}_{49}\text{H}_{53}\text{N}_3\text{O}_{10}\text{P}$ ($\text{M} + \text{H}$)⁺ 874.3469, found 874.3489.

Fluorescent-labeled compound (19b). To a solution of **19a** (30 mg, 0.034 mmol) in MeOH–EtOH (3 : 1, 8 mL) were added 1,4-cyclohexadiene (0.25 mL) and 10% Pd–C (30 mg). The reaction mixture was stirred at room temperature for 2 h. After filtration through filter paper, the solvents were removed to give the product as a colorless solid in 100% yield (21 mg): mp 42–45 °C; $[\alpha]_{\text{D}}^{20} = +72.4^\circ$ ($c = 0.5$, MeOH); ^1H NMR (500 MHz, CDCl_3) δ : 7.40–7.02 (m, 4H), 4.17–4.05 (m, 2H), 3.61–3.24 (m, 4H), 2.97–2.84 (m, 2H), 2.79–2.60 (m, 1H), 2.40–1.60 (m, 5H), 1.40–0.81 (m, 8H); ^{31}P NMR (121 MHz, CDCl_3) δ : 28.307; HRFABMS calcd. for $\text{C}_{28}\text{H}_{34}\text{N}_3\text{O}_{10}\text{P}$ (M^+) 603.1982, found 603.1969.

Tripeptide compound precursor (21a). To a suspension of aniline **13** (52 mg, 0.085 mmol) and tripeptide acid **20**⁸ (60 mg, 0.071 mmol) in CH_3CN (7 mL) were added diisopropylethylamine (18 μL , 0.106 mmol), HOAt (12 mg, 0.085 mmol) and EDCI (16 mg, 0.085 mmol). The reaction mixture was stirred at room temperature for 24 h, and then diluted with EtOAc (60 mL). The solution was washed successively with 1 N HCl (5 mL), satd. aq. NaHCO_3 (5 mL), brine (10 mL), and then dried. Following concentration, the residue was purified by flash column chromatography eluting with EtOAc–MeOH (10 : 1 to 8 : 1) to provide 91 mg of the product as a colorless oil (89%). ^1H NMR (500 MHz, CDCl_3) δ : 7.78–7.25 (m, 34 H), 7.03–6.80 (m, 3H), 5.10–4.78 (m, 12H), 4.72–4.40 (m, 3H), 4.18–3.40 (m, 7H), 2.90–2.60 (m, 6H), 2.40–2.0 (m, 4H), 2.12–1.92 (m, 12H), 1.90–1.58 (m, 14H); ^{31}P NMR (121 MHz, CDCl_3) δ : 29.522; EI-MS calcd. for $\text{C}_{79}\text{H}_{94}\text{N}_7\text{O}_{17}\text{P}$ (M^+) 1444, found 1444.

21b. Yield: 100%. $[\alpha]_{\text{D}}^{20} = -5.1^\circ$ ($c = 2.4$, MeOH); ^1H NMR (500 MHz, CD_3OD) δ : 7.54–7.38 (m, 2H), 7.20–7.11 (m, 2H), 4.43–4.02 (m, 6H), 3.78–3.40 (m, 8H), 3.84 (bs, 2H), 2.38–2.20 (m, 2H), 2.18–1.52 (m, 26H); ^{31}P NMR (121 MHz, CDCl_3) δ : 28.382; HRFABMS calcd. for $\text{C}_{37}\text{H}_{59}\text{N}_7\text{O}_{17}\text{P}$ ($\text{M} + \text{H}$)⁺ 904.3705, found 904.3675.

Acknowledgements

We thank Dr Vincent Kalish and Dr Camilo Rojas at Guilford Pharmaceuticals Inc. for generously providing the biological assays. We gratefully acknowledge financial support by the Department of Defense and collaboration with the Walther Cancer Institute as well as NIH grant AI054193 (MJM, PD). We also appreciate the use of the NMR facilities provided by the Lizzadro Magnetic Center and the mass spectrometry services (Dr W. Boggess and Ms N. Sevova) provided by the University of Notre Dame.

References

- 1 R. E. Carter and J. T. Coyle, in *Handbook of Proteolytic Enzymes*, ed. A. J. Barrett, N. D. Rawlings and J. F. Woessner, Academic, New York, 1998, pp. 1434–1437.
- 2 (a) C. Rojas, A. G. Thomas, P. Majer, T. Tsukamoto, X. M. Lu, J. J. Vornov, K. M. Wozniak and B. S. Slusher, *Adv. Exp. Med. Biol.*, 2003, **524**, 205; (b) J. H. Neale, R. T. Olszewski, L. M. Gehl, B. Wroblewska and T. Bzdega, *Trends Pharmacol. Sci.*, 2005, **26**, 477.
- 3 (a) R. E. Carter, A. R. Feldman and J. T. Coyle, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 749; (b) C. W. Tiffany, R. G. Lapidus, A. Merion, D. C. Calvin and B. S. Slusher, *Prostate*, 1999, **39**, 28; (c) E. Asatiani and E. P. Gelmann, *Expert Opin. Ther. Targets*, 2005, **9**, 283.
- 4 (a) H. Tang, M. Brown, Y. Ye, G. Huang, Y. Zhang, Y. Wang, H. Zhai, X. Chen, T. Y. Shen and M. Tenniswood, *Biochem. Biophys. Res. Commun.*, 2003, **307**, 8; (b) V. Yao and D. J. Bacich, *Prostate*, 2006, **66**, 867.
- 5 J. Zhou, J. H. Neale, M. G. Pomper and A. P. Kozikowski, *Nat. Rev. Drug Discovery*, 2005, **4**, 1015.
- 6 P. F. Jackson, D. C. Cole, B. S. Slusher, S. L. Stetz, L. E. Ross, B. A. Donzanti and D. A. Trainor, *J. Med. Chem.*, 1996, **39**, 619.
- 7 (a) A. P. Kozikowski, J. Zhang, F. Nan, P. A. Petukhov, E. Grajkowska, J. T. Wroblewski, T. Yamamoto, T. Bzdega, B. Wroblewska and J. H. Neale, *J. Med. Chem.*, 2004, **47**, 1729; (b) A. P. Kozikowski, F. Nan, P. Conti, J. Zhang, E. Ramadan, T. Bzdega, B. Wroblewska, J. H. Neale, S. Pshenichkin and J. T. Wroblewski, *J. Med. Chem.*, 2001, **44**, 298.
- 8 P. F. Jackson, K. L. Tays, K. M. MacLin, Y.-S. Ko, W. Li, D. Vitharana, T. Tsukamoto, D. Stoermer, X.-C. M. Lu, K. Wozniak and B. S. Slusher, *J. Med. Chem.*, 2001, **44**, 4170.
- 9 (a) D. W. G. Wone, J. A. Rowley, A. W. Garofalo and C. E. Berkman, *Bioorg. Med. Chem.*, 2006, **14**, 67; (b) J. P. Mallari, C. J. Choy, Y. Hu, A. R. Martinez, M. Hosaka, Y. Toriyabe, J. Maung, J. E. Blecha, S. F. Pavkovic and C. E. Berkman, *Bioorg. Med. Chem.*, 2004, **12**, 6011; (c) J. Maung, J. P. Mallari, T. A. Girtsman, L. Y. Wu, J. A. Rowley, N. M. Santiago, A. N. Brunelle and C. E. Berkman, *Bioorg. Med. Chem.*, 2004, **12**, 4969.
- 10 D. Vitharana, J. E. France, D. Scarpetti, G. W. Bonneville, P. Majer and T. Tsukamoto, *Tetrahedron: Asymmetry*, 2002, **13**, 1609.
- 11 T. Tsukamoto, P. Majer, D. Vitharana, C. Ni, B. Hin, X.-C. M. Lu, A. G. Thomas, K. M. Wozniak, D. C. Calvin, Y. Wu, B. S. Slusher, D. Scarpetti and G. W. Bonneville, *J. Med. Chem.*, 2005, **48**, 2319.
- 12 A. J. Oliver, O. Wiest, P. Helquist, M. J. Miller and M. Tenniswood, *Bioorg. Med. Chem.*, 2003, **11**, 4455. For the crystal structure of PSMA:: M. I. Davis, M. J. Bennett, L. M. Thomas and P. J. Bjorkman, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 5981.
- 13 S. F. Brady and J. Clardy, *Org. Lett.*, 2003, **5**, 121.
- 14 H. Firouzabadi, S. Etemadi, B. Karimi and A. A. Jarrahpour, *Phosphorus, Sulfur Silicon Relat. Elem.*, 1998, **143**, 45.
- 15 (a) L. J. Mathias, *Synthesis*, 1979, 561; (b) J.-M. Campagne, J. Coste and P. Jouin, *Tetrahedron Lett.*, 1993, **34**, 6743.
- 16 R. F. Newton, D. P. Reynolds, M. A. W. Finch, D. R. Kelly and S. M. Roberts, *Tetrahedron Lett.*, 1979, **20**, 3981.
- 17 S. K. Chatterjee, J. Laffray, P. Patel, R. Ravindra, Y. Qin, M. E. Kuehne and S. L. Bane, *Biochemistry*, 2002, **41**, 14010.
- 18 (a) E. K. Dolence, A. A. Minnick and M. J. Miller, *J. Med. Chem.*, 1990, **33**, 461; (b) P. Ding, N. M. Niyaz, C. E. Schous, A. Sheinkman and M. J. Miller, manuscript in preparation.
- 19 C. Barinka, M. Rinnova, P. Sacha, C. Rojas, P. Majer, B. S. Slusher and J. Konvalinka, *J. Neurochem.*, 2002, **80**, 477.
- 20 C. Rojas, S. T. Frazier, J. Flanary and B. S. Slusher, *Anal. Biochem.*, 2002, **310**, 50.